ALAnne J. M. Loonen

Anne J. M. Loonen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anne J. M. Loonen has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Adriaan J. C. van Den Brule

    Affiliation Pathologie-DNA, Lab for Molecular Diagnostics, Location Jeroen Bosch Hospital, ’s-Hertogenbosch, The Netherlands

    1 shared publication
  • Adrianus Johannes Christiaan van Den Brule

    PAMM Laboratory for Pathology

    1 shared publication
  • Angelique Ziel‐Van der Made

    Department of Pathology, Josephine Nefkens Institute, Erasmus MC, University Medical Center, Rotterdam, The Netherlands

    1 shared publication
  • Britt M. J. Meuwissen

    Affiliation Research Group Applied Natural Sciences, Fontys University of Applied Sciences, Eindhoven, The Netherlands

    1 shared publication
  • Esther Korpershoek

    Department of Pathology, Josephine Nefkens Institute, Erasmus MC, University Medical Center, Rotterdam, The Netherlands

    1 shared publication
  • Francien H van Nederveen

    Department of Pathology, Josephine Nefkens Institute, Erasmus MC, University Medical Center, Rotterdam, The Netherlands

    1 shared publication

Latest Publications

  • Trends in molecular diagnostics: 12th European Meeting on Molecular Diagnostics, Noordwijk aan Zee, the Netherlands, 12-14 October 2022

    by Anne J.M. Loonen, Rob Schuurman, Adriaan J.C. van Den Brule

    This report provides an overview of the highlights of the 12th European Meeting on Molecular Diagnostics held in Noordwijk aan Zee, The Netherlands, 12–14 October 2022. This 3-day conference covered many relevant topics in the field of molecular diagnostics in humans i.e. oncology, infectious diseases, laboratory medicine, pharmacogenetics, pathology, and preventive medicine. Other relevant topics included quality management, laboratory automation, diagnostic preparedness, and lessons learned from the COVID pandemic. More than 400 participants, the majority coming from European countries, attended the meeting. Besides high-quality scientific presentations, more than 40 diagnostic companies presented their latest innovations, altogether in an informal and inspiring ambiance.

  • Open Access

    Comprehensive analytical and clinical evaluation of a RNA extraction-free saliva-based molecular assay for SARS-CoV-2

    by Joost P. H. Schoeber, Juliëtte M. Schlaghecke, Britt M. J. Meuwissen, Mara van Heertum, Adriaan J. C. van Den Brule, Anne J. M. Loonen

    Standard SARS-CoV-2 testing protocols using nasopharyngeal/throat (NP/T) swabs are invasive and require trained medical staff for reliable sampling. In addition, it has been shown that PCR is more sensitive as compared to antigen-based tests. Here we describe the analytical and clinical evaluation of our in-house RNA extraction-free saliva-based molecular assay for the detection of SARS-CoV-2. Analytical sensitivity of the test was equal to the sensitivity obtained in other Dutch diagnostic laboratories that process NP/T swabs. In this study, 955 individuals participated and provided NP/T swabs for routine molecular analysis (with RNA extraction) and saliva for comparison. Our RT-qPCR resulted in a sensitivity of 82,86% and a specificity of 98,94% compared to the gold standard. A false-negative ratio of 1,9% was found. The SARS-CoV-2 detection workflow described here enables easy, economical, and reliable saliva processing, useful for repeated testing of individuals.


  • Conditional Pten knock‐out mice: a model for metastatic phaeochromocytoma

    by Esther Korpershoek, Anne Jm Loonen, Suzanne Corvers, Francien H van Nederveen, Jos Jonkers, Xiaoqian Ma, Angelique Ziel‐Van der Made, Hanneke Korsten, Jan Trapman, Winand Nm Dinjens, et al.

    Phaeochromocytomas (PCCs) are neuro‐endocrine tumours of the adrenal medulla that are usually benign, but approximately 10% of patients develop metastases. Malignant PCCs can only be diagnosed with certainty if metastases are present. Here we describe adrenal tumours generated in a Pten conditional knock‐out (KO) mouse model. We characterized the molecular alterations in these tumours and compared them with human PCC. Thirty‐two of 41 (78%) male Psa‐Cre;Pten‐loxP/loxP mice presented adrenal tumours that were shown to be PCC by histology and by immunohistochemical staining for enzymes in the catecholamine biosynthetic pathway. In 6 of 17 investigated mice, histological and immunohistochemical evidence was obtained for the presence of PCC lung metastases. Array comparative genomic hybridization (CGH) analysis of the primary tumours showed loss of chromosomes 6 and 19, which are syntenic to human 3p and 11q. Another frequent alteration found was gain of chromosome 15, which is syntenic to human chromosome 5. The molecular aberrations in the mouse model corresponded to the alterations found in a subtype of human PCC, suggesting that the PCC of the Pten KO mice might be representative of human PCC. The mouse model should allow further studies into the pathogenesis of human malignant PCCs and into therapeutic strategies for these tumours. Copyright © 2008 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.